News
DTIL
7.88
+0.25%
0.02
Precision BioSciences Advances Gene-Editing Programs in Hepatitis B
TipRanks · 13h ago
Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Trial Evaluating PBGENE-DMD For Duchenne Muscular Dystrophy; Initial Safety Data Targeted For End-2026
Benzinga · 14h ago
PRECISION BIOSCIENCES - INITIAL SAFETY DATA FROM FUNCTION-DMD TRIAL TARGETED FOR YEAR-END 2026 - SEC FILING
Reuters · 14h ago
Precision BioSciences posts updated corporate presentation deck on investor website
PUBT · 14h ago
Precision BioSciences announces addition to the Russell 2000 Index
TipRanks · 2d ago
PRECISION BIOSCIENCES ANNOUNCES INCLUSION IN THE RUSSELL 2000® INDEX EXPANDING MARKET VISIBILITY WITH INSTITUTIONAL INVESTORS
Reuters · 2d ago
Weekly Report: what happened at DTIL last week (0622-0626)?
Weekly Report · 2d ago
Weekly Report: what happened at DTIL last week (0615-0619)?
Weekly Report · 06/22 09:54
Precision BioSciences Extends Term Loan Maturity to 2029
TipRanks · 06/16 20:56
PRECISION BIOSCIENCES - EXTENDS TERM LOAN MATURITY DATE TO DECEMBER 31, 2029 - SEC FILING
Reuters · 06/16 20:03
Precision BioSciences extends Banc of California term loan maturity to Dec. 31, 2029
PUBT · 06/16 20:03
Weekly Report: what happened at DTIL last week (0608-0612)?
Weekly Report · 06/15 09:55
PRECISION BIOSCIENCES INC <DTIL.O>: OPPENHEIMER INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $20
Reuters · 06/09 12:53
Precision Biosciences Price Target Announced at $20.00/Share by Oppenheimer
Dow Jones · 06/09 11:43
Oppenheimer Initiates Coverage On Precision BioSciences with Outperform Rating, Announces Price Target of $20
Benzinga · 06/09 11:32
Precision BioSciences initiated with an Outperform at Oppenheimer
TipRanks · 06/09 10:55
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 06/08 17:06
Weekly Report: what happened at DTIL last week (0601-0605)?
Weekly Report · 06/08 09:52
H.C. Wainwright Reaffirms Their Buy Rating on Precision BioSciences (DTIL)
TipRanks · 06/04 00:07
Weekly Report: what happened at DTIL last week (0525-0529)?
Weekly Report · 06/01 09:55
More
Webull provides a variety of real-time DTIL stock news. You can receive the latest news about Precision Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.